Falcipain-2 inhibitors

Medicinal Research Reviews

Volumn 30, Issue 1, 2010, Pages 136-167

  Ettari, Roberta ^a   Bova, Floriana ^a   Zappalà, Maria ^a   Grasso, Silvana ^a   Micale, Nicola ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cysteine protease; Falcipain 2; Malaria; Plasmodium falciparum; Protease inhibitors

Indexed keywords

ALDEHYDE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ATOVAQUONE; AZIRIDINE DERIVATIVE; BENFLUMETOL; CHALCONE DERIVATIVE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ENZYME INHIBITOR; FALCIPAIN 2; FALCIPAIN 2 INHIBITOR; FLUOROMETHYL KETONE DERIVATIVE; HALOFANTRINE; HEMOGLOBIN; ISOQUINOLINE; ISOQUINOLINE DERIVATIVE; KETOAMIDE ALPHA DERIVATIVE; MEFLOQUINE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; SULFADOXINE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE;

CELL MEMBRANE; DISEASE TRANSMISSION; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; ENZYME STRUCTURE; ERYTHROCYTE MEMBRANE; HUMAN; IC 50; MALARIA; NONHUMAN; PHARMACOPHORE; PLASMODIUM FALCIPARUM; REVIEW; SCHIZONT; TROPHOZOITE;

EID: 84976351004     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20163     Document Type: Review

References (141)

1. World Malaria Report 2008 http://malaria.who.int/wmr2008/
2. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-685.
3. Ashley E, McGready R, Proux S, Nosten F. Malaria. Travel Med Infect Dis 2006;4:159-173.
4. Hastings IM, Bray PG, Ward SA. A requiem for chloroquine. Science 2002;298:74-75.
5. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, Su X-Z. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002;418:320-323. (Pubitemid 34790681)
6. Hemingway J, Ranson H. Insecticide resistance in insect vectors of human disease. Annu Rev Entomol 2000;45:369-389.
7. Hemingway J, Field L, Vontas J. An overview of insecticide resistance. Science 2002;298:96-97.
8. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg 2001;64:S85-S96.
9. Hartl DL. The origin of malaria: Mixed messages from genetic diversity. Nat Rev Microbiol 2004;2:15-22.
10. Mital A. Recent advances in antimalarial compounds and their patents. Curr Med Chem 2007;14:759-773. (Pubitemid 46477710)
11. Jana S, Paliwal J. Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents 2007;30:4-10. (Pubitemid 46887588)
12. Warhurst DC. Understanding resistance to antimalarial 4-aminoquinolines, cinchona alkaloids and the highly hydrophobic arylaminoalcohols. Curr Sci 2007;92:1556-1560.
13. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-218.
14. Barid JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004;48:4075-4083.
15. Rosenthal PJ, editor. Antimalarial chemotherapy: Mechanisms of action, resistance, and new directions in drug discovery. Totowa, NJ: Human Press; 2001.
16. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005;57:117-145. (Pubitemid 40283971)
17. Schlitzer M. Malaria chemotherapeutics Part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2007;2:944-986.
18. Greenwood D. The quinine connection. J Antimicrob Chemother 1992;30:417-427.
19. Egan TJ. Haemozoin (malaria pigment): A unique crystalline drug target. Targets 2003;2:115-124.
20. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci 2004;74:1957-1972.
21. Casteel DA. Antimalaria agents. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. Volume 5: Therapeutic agents. New York: Wiley; 1997. pp 3-91.
22. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharm Sci 2008;29:520-527.
23. White NJ. Antimalarial drug resistance. J Clin Invest 2004;113:1084-1092.
24. Cravo P, Culleton R, Afonso A, Ferreira ID, do Rosario VE. Mechanisms of drug resistance in malaria: current and new challenges. Anti-Infect Agents Med Chem 2006;5:63-73.
25. WHO 2007. Global AMDP database-Afro. WHO.
26. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006;1:e7.
27. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008;3:2390-2396.
28. Karema C, Fanello CI, Van Overmeir C, Van Geertruyden JP, Van Doren W, Ngamije D, D'Alessandro U. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin((R))) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006;100:1105-1111. (Pubitemid 44464010)
29. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007;2:e20. (Pubitemid 46860146)
30. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB. Randomized comparison of amodiaquine plus sulfadoxine- pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007;45:1453-1461.
31. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419:498-511.
32. Holt RA, Mani Subramanian G, Halpern A, Sutton GG, Charlab R, Nusskern DR, Wincker P, Clark AG, Ribeiro JMC, Wides R, Salzberg SL, Loftus B, Yandell M, Majoros WH, Rusch DB, Lai Z, Kraft CL, Abril JF, Anthouard V, Arensburger P, Atkinson PW, Baden H, de Berardinis V, Baldwin D, Benes V, Biedler J, Blass C, Bolanos R, Boscus D, Barnstead M, Cai S, Center A, Chatuverdi K, Christophides GK, Chrystal MA, Clamp M, Cravchik A, Curwen V, Dana A, Delcher A, Dew I, Evans CA, Flanigan M, Grundschober-Freimoser A, Friedli L, Gu Z, Guan P, Guigo R, Hillenmeyer ME, Hladun SL, Hogan JR, Hong YS, Hoover J, Jaillon O, Ke Z, Kodira C, Kokoza E, Koutsos A, Letunic I, Levitsky A, Liang Y, Lin J-J, Lobo NF, Lopez JR, Malek JA, McIntosh TC, Meister S, Miller J, Mobarry C, Mongin E, Murphy SD, O'Brochta DA, Pfannkoch C, Qi R, Regier MA, Remington K, Shao H, Sharakhova MV, Sitter CD, Shetty J, Shetty TJ, Strong R, Sun J, Thomasova D, Ton LQ, Topalis P, Tu Z, Unger MF, Walenz B, Wang A, Wang J, Wang M, Wang X, Woodford KJ, Wortman JR, Wu M, Yao A, Zdobnov EM, Zhang H, Zhao Q, Zhao S, Zhu SC, Zhimulev I, Coluzzi M, della Torre A, Roth CW, Louis C, Kalush F, Mural RJ, Myers EW, Adams MD, Smith HO, Broder S, Gardner MJ, Fraser CM, Birney E, Bork P, Brey PT, Venter JC, Weissenbach J, Kafatos FC, Collins FH, Hoffman SL. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-149.
33. Hoffman SL, Subramanian GM, Collins FH, Venter JC. Plasmodium, human and Anopheles genomics and malaria. Nature 2002;415:702-709.
34. Young JA, Winzeler EA. Using expression information to discover new drug and vaccine targets in the malaria parasite Plasmodium falciparum. Pharmacogenomics 2005;6:17-26.
35. García Liñares GE, Rodriguez JB. Current status and progresses made in malaria hemotherapy. Curr Med Chem 2007;14:289-314.
36. Goldberg DE. Hemoglobin degradation in Plasmodium-infected red blood cells. Semin Cell Biol 1993;4:355-361.
37. Liu J, Istvan ES, Gluzman IY, Gross J, Golberg DE. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci USA 2006;103:8840-8845. (Pubitemid 43878106)
38. Sherman IW, Tanigoshi L. Incorporation of 14C-amino acids by malaria (Plasmodium lophurae). Int J Biochem 1970;1:635-637.
39. Sherman IW. Amino acid metabolism and protein synthesis in malarial parasites. Bull WHO 1977;55:265-276.
40. Lew VL, Tiffert T, Ginsburg H. Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood 2003;101:4189-4194. (Pubitemid 36857903)
41. Atamna H, Ginsburg H. Origin of reactive oxygen species in erythrocytes infected with Plasmodium falciparum. Mol Biochem Parasitol 1993;61:231-241. (Pubitemid 223039723)
42. Pagola S, Stephens PW, Bhole DS, Kosar AD, Madsen SK. The structure of malaria pigment β-haematin. Nature 2000;404:307-310.
43. Francis SE, Sullivan Jr DJ, Goldberg DE. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 1997;51:97-123. (Pubitemid 27433044)
44. Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, Bajad S, Shulaev V, Sullivan Jr DJ, The role of neutral lipid nanospheres in Plasmodium falciparum heme crystallization. Biochem J 2007;402:197-204. (Pubitemid 46254920)
45. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 2002;99:990-995. (Pubitemid 34106623)
46. Sijwalai PS, Rosenthal PJ. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc Natl Acad Sci USA 2004;101:4384-4389.
47. Goldberg DE. Hemoglobin degradation. Curr Top Microbiol Immunol 2005;295:275-291.
48. Pandey AV, Singh N, Tekwani BL, Puri SK, Chauhan VS. Assay of beta-haematin formation by malaria parasite. J Pharm Biomed Anal 1999;20:203-207. (Pubitemid 29206598)
49. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest 1994;93:1602-1608. (Pubitemid 24116398)
50. Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Henderson GB. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J Exp Med 1991;173:961-969.
51. Sijwali PS, Kato K, Seydel KB, Gut J, Lehman J, Klemba M, Goldberg DE, Miller LH, Rosenthal PJ. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci USA 2004;101:8721-8726. (Pubitemid 38745838)
52. Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem 2000;275:29000-29010. (Pubitemid 30704241)
53. Sijwali PS, Shenai BR, Gut J, Singh A, Rosenthal PJ. Expression and characterization of the Plasmodium falciparum hemoglobinase falcipain-3. Biochem J 2001;360:481-489. (Pubitemid 33151343)
54. Eggleson KK, Duffin KL, Goldberg DE. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem 1999;274:32411-32417.
55. Klemba M, Gluzman I, Goldberg DE. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 2004;279:43000-43007. (Pubitemid 39372193)
56. Omara-Opyene AL, Moura PA, Sulsona CR, Bonilla JA, Yowell CA, Fujioka H, Fidock DA, Dame JB. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins emonstrates their functional redundancy. J Biol Chem 2004;279:54088-54096. (Pubitemid 40053143)
57. Glushakova S, Mazar J, Hohmann-Marriott MF, Hama E, Zimmerberg J. Irreversible effect of cysteine protease inhibitors on the release of malaria parasites from infected erythrocytes. Cell Microbiol 2009;11:95-105.
58. Gavigan CS, Dalton JP, Bell A. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 2001;117:37-48. (Pubitemid 32823481)
59. Dalal S, Klemba M. Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum. J Biol Chem 2007;282:35978-35987. (Pubitemid 350277126)
60. Singh N, Sijwali PS, Pandey KC, Rosenthal PJ. Plasmodium falciparum: Biochemical characterization of the cysteine protease falcipain-2'. Exp Parasitol 2006;112:187-192. (Pubitemid 43247780)
61. Rosenthal PJ. Cysteine proteases of malaria parasites. Int J Parasitol 2004;34:1489-1499.
62. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, Engel J, DeRisi J, Holder AA, Bogyo M. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 2002;298:2002-2006. (Pubitemid 35425258)
63. Eksi S, Czesny B, Greenbaum DC, Bogyo M, Williamson KC. Targeted disruption of Plasmodium falciparum cysteine protease, falcipain 1, reduces oocyst production, not erythrocytic stage growth. Mol Microbiol 2004;53:243-250. (Pubitemid 38901394)
64. Ramjee MK, Flinn NS, Pemberton TP, Quibell M, Wang Y, Watts JP. Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. Biochem J 2006;399:47-57. (Pubitemid 44505406)
65. Dahl EL, Rosenthal PJ. Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol 2005;139:205-212. (Pubitemid 40128216)
66. Krungkrai J, Prapunwattana P, Krungkrai SR. Ultrastructure and function of mitochondria in gametocytic stage of Plasmodium falciparum. Parasite 2000;33:19-26.
67. Hanspal M, Dua M, Takakuwa Y, Chishti AH, Mizuno A. Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. Blood 2002;100:1048-1054. (Pubitemid 34832636)
68. Sijwali PS, Koo J, Singh N, Rosenthal PJ. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum.Mol Biochem Parasitol 2006;150:96-106.
69. Nielsen KM, Kasper J, Choi M, Bedford T, Kristiansen K, Wirth DF, Volkman SK, Lozovsky ER, Hartl DL. Gene conversion as a source of nucleotide diversity in Plasmodium falciparum. Mol Biol Evol 2003;20:726-734. (Pubitemid 36539008)
70. Goh LL, Sim TS. Characterization of amino acid variation at strategic positions in parasite and human proteases for selective inhibition of falcipains in Plasmodium falciparum. Biochem Biophys Res Commun 2005;335:762-770.
71. Jeong JJ, Kumar A, Hanada T, Seo PS, Li X, Hanspal M, Chishti AH. Cloning and characterization of Plasmodium falciparum cysteine protease, falcipain-2B. Blood Cells Mol Dis 2006;3:429-435. (Pubitemid 43776187)
72. Drew ME, Banerjee R, Uffman EW, Gilbertson S, Rosenthal PJ, Goldberg DE. Plasmodium food vacuole plasmepsins are activated by falcipains. J Biol Chem 2008;283:12870-12876.
73. Hogg T, Nagarajan K, Herzberg S, Chen L, Shen X, Jiang H, Wecke M, Blohmke C, Hilgenfeld R, Schmidt CL. Structural and functional characterization of falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J Biol Chem 2006;281:25425-25437. (Pubitemid 44401931)
74. Wang SX, Pandey KC, Somoza JR, Sijwali PS, Kortemme T, Brinen LS, Fletterick RJ, Rosenthal PJ, McKerrow JH. Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc Natl Acad Sci USA 2006;103:11503-11508. (Pubitemid 44182481)
75. Kerr ID, Lee JH, Pandey KC, Harrison A, Sajid M, Rosenthal PJ, Brinen LS. Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J Med Chem 2009;52:852-857.
76. Sabnis Y, Rosenthal PJ, Desai P, Avery MA. Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J Biomol Struct Dyn 2002;19:765-774. (Pubitemid 34475607)
77. Sijwali PS, Shenai BR, Rosenthal PJ. Folding of the Plasmodium falciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain. J Biol Chem 2002;277:14910-14915.
78. Powers JC, Asgian JL, Ekiei OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002;102:4639-4750.
79. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest 1988;82:1560-1566. (Pubitemid 19007759)
80. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. Antimalarial effects of peptide inhbitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest 1991;88:1467-1472.
81. Rosenthal PJ, Lee GK, Smith RE. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J Clin Invest 1993;91:1052-1056.
82. Palmer JT, Rasnick D, Klaus JK, Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995;38:3193-3196.
83. Vicik R, Busemann M, Baumann K, Schirmeister T. Inhibitors of cysteine proteases. Curr Top Med Chem 2006;6:331-353.
84. Rosenthal PJ, Olson JE, Lee GK, Palmer JT, Klaus JL, Rasnick D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob Agents Chemother 1996;40:1600-1603. (Pubitemid 26227342)
85. Olson JE, Lee GK, Semenov A, Rosenthal PJ. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg Med Chem 1999;7:633-638. (Pubitemid 29150306)
86. Shenai BR, Lee BJ, Alvarez-Hernandez A, Chong PY, Emal CD, Neitz RJ, Roush WR, Rosenthal PJ. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob Agents Chemother 2003;47:154-160. (Pubitemid 36070357)
87. Lee BJ, Singh A, Chiang P, Kemp SJ, Goldman EA, Weinhouse MI, Vlasuk GP, Rosenthal PJ. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob Agents Chemother 2003;47:3810-3814. (Pubitemid 37484994)
88. Barrett AJ, Rawlings ND, Woessner JF. Handbook of proteolytic enzymes. San Diego, CA: Academic Press; 1998.
89. Rosenthal PJ, Sijwali PS, Singh A, Shenai BR. Cysteine proteases of malaria parasites: Targets for chemotherapy. Curr Pharm Des 2002;8:1659-1672. (Pubitemid 34752832)
90. Singh A, Shenai BR, Choe Y, Gut J, Sijwali PS, Craik CS, Rosenthal PJ. Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. Biochem J 2002;368:273-281. (Pubitemid 35463430)
91. Hanada K, Tamai M, Yamagishi S, Ohmura S, Sawada J, Tanaka I. Isolation and characterization of E-64, a new thiol protease inhibitor. Agric Biol Chem 1978;42:523-528. (Pubitemid 8343851)
92. Hanada K, Tamai M, Yamagishi S, Ohmura S, Sawada J, Tanaka I. Studies on thiol protease inhibitors. Part II. Structure and synthesis of E-64, a new thiol protease inhibitor. Agric Biol Chem 1978;42:529-536.
93. Inaba T, Hirayama Y, Fujinaga N. Inhibition of cathepsin B1 by E-64, a thiol proteinase inhibitor, and its derivatives. Agric Biol Chem 1979;43:655-656.
94. Towatari T, Tanaka K, Yoshikawa D, Katunuma N. Purification and properties of a new cathepsin from rat liver. J Biochem 1978;84:659-672. (Pubitemid 9013297)
95. Sugita H, Ishiura S, Suzuki K, Imahori K. Inhibition of epoxide derivatives on chicken calcium-activated neutral protease (CANP) in vitro and in vivo. J Biochem 1980;87:339-341. (Pubitemid 10138348)
96. Suzuki K. Reaction of calcium-activated neutral protease (CANP) with an epoxysuccinyl derivative (E64c) and iodoacetic acid. J Biochem 1983;93:1305-1312.
97. Roush WR, Hernandez AA, McKerrow JH, Selzer PM, Hansell E, Engel JC. Design, synthesis and evaluation of D-homophenylalanyl epoxysuccinate inhibitors of the trypanosomal cysteine protease cruzain. Tetrahedron 2000;56:9747-9762.
98. Buttle DJ, Saklatvala J, Tamai M, Barrett AJ. Inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by a lipophilic inactivator of cysteine endopeptidases. Biochem J 1992;281:175-177.
99. Kembhavi AA, Buttle DJ, Knight CG, Barrett AJ. The two cysteine endopeptidases of legume seeds: Purification and characterization by use of specific fluorometric assays. Arch Biochem Biophys 1993;303:208-213.
100. Chen Z, Potempa J, Polanowski A, Wikstrom M, Travis J. Purification and characterization of a 50-kDa cysteine proteinase (gingipain) from Porphyromonas gingivalis. J Biol Chem 1992;267:18896-18901.
101. Nikawa T, Towatari T, Katunuma N. Purification and characterization of cathepsin J from rat liver. Eur J Biochem 1992;204:381-393.
102. Schulz F, Gelhaus C, Degel B, Vicik R, Heppner S, Breuning A, Leippe M, Gut J, Rosenthal PJ, Schirmeister T. Screening of protease inhibitors as antiplasmodial agents. Part I: aziridines and epoxides. ChemMedChem 2007;2:1214-1224.
103. Roush WR, González FV, McKerrow JH, Hansell E. Design and synthesis of dipeptidyl α',β'- epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain. Bioorg Med Chem Lett 1998;8:2809-2812.
104. James HK, Asgian JL, Li ZZ, Ekici OD, Rubin JR, Mikolajczyk J, Salvesen GS, Powers JC. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J Med Chem 2004;47:1553-1574.
105. Yabe Y, Guillaume D, Rich DH. Irreversible inhibition of papain by epoxysuccinyl peptides. Carbon-13 NMR characterization of the site of alkylation. J Am Chem Soc 1988;110:4043-4044.
106. Matsumoto K, Yamamoto D, Ohishi H, Tomoo K, Ishida T, Inoue M, Sadatome T, Kitamura K, Mizuno H. Mode of binding of E-64-c, a potent thiol protease inhibitor, to papain as determined by X-ray crystal analysis of the complex. FEBS Lett 1989;245:177-180.
107. Greenbaum D, Medzihradszky K, Burlingame A, Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 2000;7:569-581.
108. Varughese KI, Ahmed FR, Carey PR, Hasnain S, Huber CP, Storer AC. Crystal structure of a papain-E-64 complex. Biochemistry 1989;28:1330-1332.
109. Varughese KI, Su Y, Cromwell D, Hasnain S, Xuong NH. Crystal structure of an actinidin-E-64 complex. Biochemistry 1992;31:5172-5176.
110. Mladenovic M, Schirmeister T, Thiel S, Thiel W, Engels B. The importance of the active site histidine for the activity of epoxide- or aziridine-based inhibitors of cysteine proteases. Chem Med Chem 2007;2:120-128.
111. Schirmeister T, Kaeppler U. Non-peptidic inhibitors of cysteine proteases. Mini Rev Med Chem 2003;3:361-373.
112. Martichonok V, Plouffe C, Storer AC, Menard R, Jones JB. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases. J Med Chem 1995;38:3078-3085.
113. Bucciarelli M, Forni A, Moretti I, Prati F, Torre G. Candida cylindracea lipase-catalyzed hydrolysis of methyl aziridine-2-carboxylates and -2,3-dicarboxylates. Tetrahedron Asymm 1993;4:903-906.
114. Bucciarelli M, Forni A, Moretti I, Prati F, Torre G. Candida cylindracea lipase-catalyzed hydrolysis of methyl aziridine-2-carboxylates and -2,3-dicarboxylates. J Chem Soc Perkin Trans 1 1993; 3041-3045.
115. Vicik R, Helten H, Schirmeister T, Engels B. Rational design of aziridine containing cysteine protease inhibitors with improved potency studies on inhibition mechanism. ChemMedChem 2006;1:1021-1028.
116. Dermer OC, Ham GE. Ethyleneimine and other aziridines. New York: Academic Press; 1969. p 106.
117. Schirmeister T. Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks. Biopolymers 1999;51:87-97.
118. Schirmeister T. New peptidic cysteine protease inhibitors derived from the electrophilic a-amino acid aziridine-2,3-dicarboxylic acid. J Med Chem 1999;42:560-572.
119. Moroder L, Musiol HJ, Scharf R. Aziridine-2-carboxylic acid. A reactive amino acid unit for a new class of cysteine proteinase inhibitors. FEBS Lett 1992;299:51-53.
120. Souers AJ, Ellman JA. β-Turn mimetic library synthesis: Scaffolds and applications. Tetrahedron 2001;57:7431-7448.
121. Burgess K. Solid-phase syntheses of β-turn analogues to mimic or disrupt protein-protein interactions. Acc Chem Res 2001;34:826-835.
122. MacDonald M, Aubé J. Approaches to cyclic peptide β-turn mimics. Curr Org Chem 2001;5:417-438.
123. Eguchi M, Kahn M. Design, synthesis, and application of peptide secondary structure mimetics. Mini Rev Med Chem 2002;2:447-462.
124. Dziadulewicz EK, Brown MC, Dunstan AR, Lee W, Said NB, Garratt PJ. The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg Med Chem Lett 1999;9:463-468.
125. Lauffer DJ, Mullican MD. A practical synthesis of (S) 3-tert-butoxycarbonylamino-2- oxo-2,3,4,5-tetrahydro-1,5-benzodiazepine-1-acetic acid methyl ester as a conformationally restricted dipeptido-mimetic for caspase-1 (ICE) inhibitors. Bioorg Med Chem Lett 2002;12:1225-1227.
126. Micale N, Kozikowski AP, Ettari R, Grasso S, Zappalà M, Jeong J-J, Kumar A, Hanspal M, Chishti AH. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J Med Chem 2006;49:3064-3067.
127. Ettari R, Nizi E, Di Francesco ME, Dude MA, Pradel G, Vičík R, Schirmeister T, Micale N, Grasso S, Zappalà M. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. J Med Chem 2008;51:988-996. (Pubitemid 351304707)
128. Ettari R, Nizi E, Di Francesco ME, Micale N, Grasso S, Zappalà M, Vičík R, Schirmeister T. Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors. ChemMedChem 2008;3:1030-1033.
129. Verissimo E, Berry N, Gibbons P, Cristiano MLS, Rosenthal PJ, Gut J, Ward SA, O'Neill PM. Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. Bioorg Med Chem Lett 2008;18:4210-4214.
130. Chen M, Theander TG, Christensen BS, Hviid L, Zhai L, Kharazmi A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother 1994;38:1470-1475. (Pubitemid 24203554)
131. Chen M, Christensen SB, Zhai L, Rasmussen MH, Theander TG, Frokjaer S, Steffansen S, Davidsen J, Kharazmi A. The novel oxygenated chalcone, 2,4-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis 1997;176:1327-1333.
132. Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Domìnguez JN, Davidson E, Kurzban G, Miller RE, Nuzum EO, Rosenthal PJ, McKerrow JH. In vitro antimalarial activity of chalcones and their derivatives. J Med Chem 1995;38:5031-5037.
133. Liu M, Wilairat P, Go ML. Antimalarial alkoxylated and hydroxylated chalcones: Structure-activity relationship analysis. J Med Chem 2001;44:4443-4452. (Pubitemid 33131668)
134. Domìnguez JN, Leòn C, Rodrigues J, Domìnguez NG, Gut J, Rosenthal PJ. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivate. J Med Chem 2005;48:3654-3658. (Pubitemid 40664115)
135. Motta LF, Gaudio AC, Takahata Y. Quantitative structure-activity relationships of a series of chalcone derivatives (1,3-diphenyl-2-propen-1-one) as anti Plasmodium falciparum agents (anti malaria agents). Internet Electron J Mol Des 2006:5;555-569.
136. Sajid M, McKerrow JH. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 2002;120:1-21-29.
137. Batra S, Sabnis YA, Rosenthal PJ, Avery MA. Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. Bioorg Med Chem 2003;11:2293-2299.
138. Klayman DL, Bartosevich JF, Griffin TS, Mason CJ, Scovill JP. 2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents. J Med Chem 1979;22:855-862.
139. Chiyanzu I, Hansell E, Gut J, Rosenthal PJ, McKerrowb JH, Chibale K. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett 2003;13:3527-3530. (Pubitemid 37141422)
140. Greenbaum DC, Mackey Z, Hansell E, Doyle P, Gut J, Caffrey CR, Lehrman J, Rosenthal PJ, McKerrow JH, Chibale K. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem 2004;47:3212-3219. (Pubitemid 38702713)
141. Chipeleme A, Gut J, Rosenthal PJ, Chibale K. Synthesis and biological evaluation of phenolic Mannich bases of benzaldehyde and (thio)semicarbazone derivatives against the cysteine protease falcipain-2 and a chloroquine resistant strain of Plasmodium falciparum. Bioorg Med Chem 2007;15:273-282. (Pubitemid 44738573)